Investment Rating - The report maintains a "Buy" rating for the company, with a target price based on projected earnings growth and market performance [4][11]. Core Insights - The company reported steady growth in revenue and net profit for the first half of 2024, with total revenue reaching 2.689 billion yuan, a year-on-year increase of 6.21%, and a net profit attributable to shareholders of 152 million yuan, up 1.14% [2]. - The medical aesthetics segment showed robust growth, generating 1.194 billion yuan in revenue, a 6.02% increase year-on-year, with a gross margin of 54.23% [3]. - The women's clothing segment achieved a double-digit growth rate, with revenue of 1.012 billion yuan, reflecting an 11.41% year-on-year increase [3]. - The company is actively expanding its medical aesthetics business through acquisitions, including the purchase of 100% of Beijing Lido and 70% of Hunan Yamei, with respective valuations of 330 million yuan and 360 million yuan [3]. Financial Performance Summary - For the first half of 2024, the company achieved a revenue of 2.689 billion yuan, with a net profit of 152 million yuan, and a non-recurring net profit of 140 million yuan, marking an 11.49% increase year-on-year [2]. - The forecasted earnings per share (EPS) for 2024, 2025, and 2026 are projected to be 0.72 yuan, 0.84 yuan, and 0.98 yuan respectively, with corresponding price-to-earnings ratios (PE) of 18, 15, and 13 times [4]. - The company’s total revenue is expected to grow from 5.902 billion yuan in 2024 to 7.212 billion yuan in 2026, with a compound annual growth rate (CAGR) of approximately 7.84% [5][10]. Business Segments Overview - The medical aesthetics segment is expanding with a focus on community-based services, having established 38 medical beauty institutions by the end of the reporting period [3]. - The women's clothing segment continues to perform well, contributing significantly to overall revenue growth [3]. - The infant and child segment experienced a decline in revenue, amounting to 450 million yuan, a decrease of 4.13% year-on-year [3].
朗姿股份:2024年中报点评:上半年业绩稳健,医美外延并购持续落地